These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 16401284)

  • 1. Counterfactual links to the proportion of treatment effect explained by a surrogate marker.
    Taylor JM; Wang Y; Thiébaut R
    Biometrics; 2005 Dec; 61(4):1102-11. PubMed ID: 16401284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating surrogate markers.
    Hughes MD; DeGruttola V; Welles SL
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995; 10 Suppl 2():S1-8. PubMed ID: 7552506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantifying the indirect treatment effect via surrogate markers.
    Qu Y; Case M
    Stat Med; 2006 Jan; 25(2):223-31. PubMed ID: 16143992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating surrogate markers of clinical outcome when measured with error.
    Dafni UG; Tsiatis AA
    Biometrics; 1998 Dec; 54(4):1445-62. PubMed ID: 9883544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing surrogates as trial endpoints using mixed models.
    Korn EL; Albert PS; McShane LM
    Stat Med; 2005 Jan; 24(2):163-82. PubMed ID: 15515150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incorporating durability information in the comparison of proportions of patients with HIV suppression.
    Chen YH; Nessly ML; Thiyagarajan B
    J Biopharm Stat; 2004 Aug; 14(3):741-55. PubMed ID: 15468762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiretroviral effects on HIV-1 RNA, CD4 cell count and progression to AIDS or death: a meta-regression analysis.
    Mills EJ; Kelly S; Bradley M; Mollon P; Cooper C; Nachega J
    HIV Med; 2008 Nov; 9(10):849-57. PubMed ID: 18795965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical issues for HIV surrogate endpoints: point/counterpoint. An NIAID workshop.
    Albert JM; Ioannidis JP; Reichelderfer P; Conway B; Coombs RW; Crane L; Demasi R; Dixon DO; Flandre P; Hughes MD; Kalish LA; Larntz K; Lin D; Marschner IC; Muñoz A; Murray J; Neaton J; Pettinelli C; Rida W; Taylor JM; Welles SL
    Stat Med; 1998 Nov; 17(21):2435-62. PubMed ID: 9819838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does the Prentice criterion validate surrogate endpoints?
    Berger VW
    Stat Med; 2004 May; 23(10):1571-8. PubMed ID: 15122737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proportion of treatment effect (PTE) explained by a surrogate marker.
    Chen C; Wang H; Snapinn SM
    Stat Med; 2003 Nov; 22(22):3449-59. PubMed ID: 14601012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simulation studies of surrogate endpoint validation using single trial and multitrial statistical approaches.
    Lassere M; Johnson K; Hughes M; Altman D; Buyse M; Galbraith S; Wells G
    J Rheumatol; 2007 Mar; 34(3):616-9. PubMed ID: 17343308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint.
    Baker SG
    Biostatistics; 2006 Jan; 7(1):58-70. PubMed ID: 15972889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Parametric randomization-based methods for correcting for treatment changes in the assessment of the causal effect of treatment.
    Walker AS; White IR; Babiker AG
    Stat Med; 2004 Feb; 23(4):571-90. PubMed ID: 14755390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjusting for differential proportions of second-line treatment in cancer clinical trials. Part I: structural nested models and marginal structural models to test and estimate treatment arm effects.
    Yamaguchi T; Ohashi Y
    Stat Med; 2004 Jul; 23(13):1991-2003. PubMed ID: 15211598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sample size for testing difference between two proportions for the bilateral-sample design.
    Qiu SF; Tang NS; Tang ML; Pei YB
    J Biopharm Stat; 2009 Sep; 19(5):857-71. PubMed ID: 20183448
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating probit models with self-selected treatments.
    Bhattacharya J; Goldman D; McCaffrey D
    Stat Med; 2006 Feb; 25(3):389-413. PubMed ID: 16382420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On corrected score approach for proportional hazards model with covariate measurement error.
    Song X; Huang Y
    Biometrics; 2005 Sep; 61(3):702-14. PubMed ID: 16135021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Statistical evaluation of biomarkers as surrogate endpoints: a literature review.
    Weir CJ; Walley RJ
    Stat Med; 2006 Jan; 25(2):183-203. PubMed ID: 16252272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD4+ guided antiretroviral treatment interruption in HIV infection: a meta-analysis.
    Seminari E; De Silvestri A; Boschi A; Tinelli C
    AIDS Rev; 2008; 10(4):236-44. PubMed ID: 19092979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Missing data methods for the assessment of surrogate outcomes and treatment mechanisms in clinical trial substudies.
    Galbraith S; Marschner IC; Simes J
    Stat Med; 2006 Feb; 25(3):415-31. PubMed ID: 16217855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.